icad inc. (NASDAQ:ICAD) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.

Separately, Laidlaw reaffirmed a “buy” rating and issued a $11.00 price objective on shares of icad inc. in a research note on Tuesday, July 25th.

Shares of icad inc. (ICAD) traded down 1.28% during mid-day trading on Thursday, reaching $3.87. The company’s stock had a trading volume of 16,386 shares. icad inc. has a 12-month low of $2.82 and a 12-month high of $6.15. The stock’s market capitalization is $64.22 million. The company’s 50-day moving average price is $3.78 and its 200-day moving average price is $4.34.

icad inc. (NASDAQ:ICAD) last released its quarterly earnings data on Tuesday, August 8th. The technology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. The business had revenue of $6.41 million for the quarter, compared to the consensus estimate of $6.41 million. On average, equities research analysts forecast that icad inc. will post ($0.54) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/07/icad-inc-icad-downgraded-by-valuengine.html.

In related news, Director Dr Lawrence Howard bought 10,000 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were purchased at an average price of $3.33 per share, with a total value of $33,300.00. Following the transaction, the director now owns 488,022 shares in the company, valued at approximately $1,625,113.26. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 19.10% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Argent Capital Management LLC increased its position in shares of icad inc. by 13.2% during the 2nd quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock valued at $2,990,000 after purchasing an additional 82,967 shares during the last quarter. Vanguard Group Inc. increased its position in shares of icad inc. by 0.4% during the 2nd quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock valued at $1,912,000 after purchasing an additional 2,007 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its position in shares of icad inc. by 822.3% during the 2nd quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock valued at $586,000 after purchasing an additional 124,612 shares during the last quarter. 23.74% of the stock is currently owned by hedge funds and other institutional investors.

About icad inc.

iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.